Found "Health Policies": 995 results
Sort by
Sort by
Z - A
Avoiding health technology assessment: a global survey of reasons for not using health technology assessment in decision making
Abstract
Introduction
Despite the documented benefits of using health technology assessments (HTA) to inform resource allocation in health care systems, HTA remains underused, especially in low- and middle-income countries. A survey of global health practitioners was conducted to reveal the top
At 4500 miles apart, Thailand joins the Kenyan UHC Fund Taskforce Meeting
On 21st September 2020, HITAP joined representatives of the Ministry of Public Health (MOPH) Thailand and the National Health Security Office (NHSO) at the Kenyan Universal Health Coverage (UHC) Fund Taskforce meeting chaired by Mr. Geoffrey Malombe from National Treasury and Dr. Mercy Mwangangi, Ch
Assessment of HTA capacity in Africa
HITAP, in collaboration with the Center for the Evaluation of Value and Risk in Health, Tufts Medical Cent, conducted an analysis of existing capacity for conducting economic evaluations in the African region using the Tufts Medical Center CEA Registries. The findings of the study were presented at the PMAC 2020 side meeting “Attain & Sustain
Assessment of Health Technology Assessment Capacity in Africa
HITAP, in collaboration with the Center for the Evaluation of Value and Risk in Health, Tufts Medical Cent, conducted an analysis of existing capacity for conducting economic evaluations in the African region using the Tufts Medical Center CEA Registries. The findings of the study were presented at the PMAC 2020 side meeting “Attain & Sustain
Assessment of Capacity Building of Member States of WHO South-East Asia Region in Global Health
The term “global health” has emerged as part of the larger political and historical process, replacing the term “international health” to imply a shared global responsibility for health and is also associated with the growing number and increased roles of other actors beyond governments. In September 2009, Director-General of WHO, in consul
Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?
Abstract
Background and Objectives
The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m
Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?
Abstract
Background and Objectives
The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m
10 / Page